| 摘要 |
The invention features methods of identifying patients as being likely to respond to anti- VEGF therapy. Furthermore, in those patients identified as failing to include one or more of the above ophthalmic response markers, the invention features treatment with an EPO antagonist (e.g., alone, or in combination with a VEGF antagonist). |
